Complex suppressive therapy of herpetic infection
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective was to analyze the effectiveness of suppressive therapy of frequently recurring forms of herpetic infection, including a preparation containing valaciclovir and inducer of endogenous interferon – Overin.
Materials and methods. Under observation for 6 months were 42 patients with frequently recurring forms of herpetic infection. The patients were divided into groups depending on the treatment regimens. The main group included 22 patients, the comparison group - 20. The control group consisted of 30 healthy people. Patients of the main group with frequently recurring forms of herpes (more than 6 relapses per year) received suppressive therapy with valoacyclovir, additionally they were prescribed Overin. Patients in the comparison group received standard suppressive therapy for 60 days, including a preparation containing valacyclovir.
Results. The reasons of occurrence and a technique of treatment of chronic frequently recurring forms of herpesvirus infection were studied. An etiopathogenetically substantiated method for treating diseases caused by the herpes simplex virus has been developed.
The conclusion. The use of Overin in the complex therapy of the recurring forms of herpetic infection is ethiopathogenetically justified. The drug effectively improves the immune parameters of the blood and the general condition of the patients.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Драник Г.Н. Клиническая иммунология и аллергология: пособие для студентов, врачей-интернов, иммунологов, аллергологов, врачей лечебного профиля всех специальностей. – 4-е изд., доп. – К., 2010 – 552 с.
Запольский М.Э. Герпесвирусные заболевания (альфа-, бета-, гамма-подгруппы): научное издание/ М.Э. Запольский. – Одесса; Фото-синтетика, 2010. – 285 с.
Иванова М.Ф. Постгерпетическая опоясывающая невралгия и ее лечение амантадином (ПК-МЕРЦ) (Научный обзор) / М.Ф. Иванова, И.С. Евтушенко, О.А. Макарчук // Міжнародний неврологічний журнал. – 2012. – No 8 (54). – С. 77–84.
Исаков В.А. Герпесвирусная инфекция: Рекомендации для врачей /В.А. Исаков, С.Б. Рыбалкин, М.Г. Романцов: – СПб., 2006. –96 с.
Исаков В.А. Патогенез и лечение социально значимых вирусных урогенитальных инфекций (герпеса и папилломавирусной инфекции)/ В.А. Исаков, Д.В. Исаков // Клиническая фармакология и терапия. – 2014. – No 23 (1). – С. 7–13.
Менделевич Е.Г. Постгерпетическая невралгия: лечебно-профилактические аспекты и терапия прегабалином / Е.Г. Менделевич, С.В. Менделевич // Неврология, нейропсихиатрия, психосоматика. – 2014. – No 2. – С. 57–61.
Осипова Л.С.Особенности течения постгерпетических осложнений и их лечение на современном этапе / Л.С. Осипова, М.Т. Матюха [и др.] // Новости медицины и фармации. – К., 2007. – No 15 (221). – С. 13–14.
Самгин М.А. Простой герпес, дерматологические аспекты / М.А. Самгин, А.А. Халдин. – М.: Медпресс-информ, 2002. – С. 91–92.
Современные подходы к терапии постгерпетической невралгии тройничного нерва / О.А. Степанченко, М.Н. Шаров, М.Ю. Максимова [и др.] // Consilium medicum. – 2013. – Том 15, No 2. – С. 106–108.
Coulson S. Prognostic factors in herpes zoster oticus (ramsay hunt syndrome) / S. Coulson, G.R. Croxson, R. Adams, V. Oey // Otol. Neurotol. – 2011. – Vol. 32 (6). – P. 1025–1030.
Harden R.N. Evidence-based guidance for the management of postherpetic neuralgia in primary care /R.N. Harden, A.D. Kaye, T. Kintanar, C.E. Argoff // Postgrad. Med. – 2013. – Vol. 125(4). – P. 191–202.
Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective / R.W. Johnson, M.-J. Alvarez-Pasquin, M. Bijl [et al.] // Ther. Adv. Vaccines. – 2015. – Vol. 3 (4). – P. 109–120.
Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study / W. Lapolla, C. Digiorgio, K. Haitz [et al.] // Arch. Dermatol. – 2011. – Vol. 147 (8). – P. 901–907.
James S.H. Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection / S.H. James, D.W. Kimberlin, R.J. Whitley // Antiviral Research. – 2009. – Vol. 83, No 3. – P. 207–213.
Massengill J.S. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider /J.S. Massengill, J.L. Kittredge // J. Pain Res. – 2014. – Vol. 7. – P. 125–132.
Porta C. Mechanisms linking pathogens-associated inflammation and cancer / C. Porta, E. Riboldi, A. Sica // Cancer Letters. – 2011. – Vol. 305, No 2. – P. 250–262.
Ramsay Hunt syndrome: our experience / R.L. Boemo, M.L. Navarrete, A.M. Garcнa-Arumн [et al.] // Acta Otorrinolaringol. Esp. – 2010. – Vol. 61 (6). – P. 418–21.
Saarto T. Antidepressants for neuropathic pain: a Cochrane review / T. Saarto, P.J. Wiffen //J. Neurol. Neurosurg. Psychiatry. – 2010. – Vol. 81 (12). – P. 1372–1373.
